These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 8475358)

  • 1. [Unexpectedly prolonged thrombin time].
    Barth A; Furlan M; Lämmle B
    Schweiz Med Wochenschr; 1993 Mar; 123(12):523-9. PubMed ID: 8475358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Increased thrombin time in a patient with multiple myeloma].
    Bohler A; Redondo M; Lämmle B
    Ther Umsch; 1999 Sep; 56(9):491-4. PubMed ID: 10517116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The importance of simple coagulation tests (fibrinogen assays and thrombin coagulase clotting time) in the diagnosis of liver cancer.
    Pengo V; Levi Minzi S; Dal Bo Zanon R; Cappellato G; Farinati F; Girolami A
    J Med; 1984; 15(2):149-60. PubMed ID: 6096471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Acquired dysfibrinogenemia in a child in the course of a liver disease].
    Maak B; Meyer M; Dietze H
    Monatsschr Kinderheilkd; 1990 Aug; 138(8):446-50. PubMed ID: 2215508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated fibrinogen in an acute phase reaction prolongs the reptilase time but typically not the thrombin time.
    Van Cott EM; Smith EY; Galanakis DK
    Am J Clin Pathol; 2002 Aug; 118(2):263-8. PubMed ID: 12162688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibrinogen St. Gallen I (gamma 292 Gly--> Val): evidence for structural alterations causing defective polymerization and fibrinogenolysis.
    Stucki B; Schmutz P; Schmid L; Haeberli A; Lämmle B; Furlan M
    Thromb Haemost; 1999 Feb; 81(2):268-74. PubMed ID: 10064005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibrinogens Bern IV, Bern V and Milano XI: three dysfunctional variants with amino acid substitutions in the thrombin cleavage site of the Aalpha-chain.
    Stucki B; Zenhäusern R; Biedermann B; Baudo F; Redaelli R; Lämmle B; Furlan M
    Blood Coagul Fibrinolysis; 1999 Mar; 10(2):93-9. PubMed ID: 10192658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determination of Fibrinogen and Thrombin Time (TT).
    Undas A
    Methods Mol Biol; 2017; 1646():105-110. PubMed ID: 28804822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The seial thrombin time in the diagnosis of consumptive coagulopathy.
    Alonso KB
    Ann Clin Lab Sci; 1978; 8(3):228-33. PubMed ID: 655608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparison of coagulation screening test results in two cases having dysfibrinogen].
    Terasawa F; Sasaki Y; Ishikawa S; Nakagoshi R; Furihata K; Katsuyama T; Okumura N
    Rinsho Byori; 1996 Aug; 44(8):791-6. PubMed ID: 8816067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A study of impaired fibrin polymerization in patients with the nephrotic syndrome.
    Mysliwiec M; Ralston A; Ackrill P; Poller L
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1990; 117(1):73-8. PubMed ID: 1695187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombin clotting time.
    Ignjatovic V
    Methods Mol Biol; 2013; 992():131-8. PubMed ID: 23546710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [An analysis of a disorder in the fibrin-forming phase in virtually healthy middle-aged and elderly subjects by using the ancistron test].
    Platonova TN; Sushko OO; Lukinova NI; Solovĭov DA
    Fiziol Zh (1994); 1994; 40(3-4):63-70. PubMed ID: 7621957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of thrombin in plasma by heparin or arginine.
    Stief TW
    Clin Appl Thromb Hemost; 2007 Apr; 13(2):146-53. PubMed ID: 17456623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dysfibrinogenemia in a patient with primary hepatoma. First observation of an acquired abnormality of fibrin monomer aggregation.
    von Felten A; Straub PW; Frick PG
    N Engl J Med; 1969 Feb; 280(8):405-9. PubMed ID: 4303132
    [No Abstract]   [Full Text] [Related]  

  • 16. Rare inherited disorders of fibrinogen.
    Acharya SS; Dimichele DM
    Haemophilia; 2008 Nov; 14(6):1151-8. PubMed ID: 19141154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The rapid determination of fibrin and fibrinogen split products with a bedside thrombin coagulase time test in obstetric coagulopathies (author's transl)].
    Kastendieck E; Barthels M
    Geburtshilfe Frauenheilkd; 1974 Sep; 34(9):758-62. PubMed ID: 4437565
    [No Abstract]   [Full Text] [Related]  

  • 18. Acquired dysfibrinogenemia secondary to multiple myeloma.
    Kotlín R; Sobotková A; Riedel T; Salaj P; Suttnar J; Reicheltová Z; Májek P; Khaznadar T; Dyr JE
    Acta Haematol; 2008; 120(2):75-81. PubMed ID: 18841003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Role of newly developed technology in blood coagulation disorders].
    Matsuo T
    Rinsho Byori; 2002 May; 50(5):506-12. PubMed ID: 12078050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A novel molecular marker for thrombus formation and life prognosis--clinical usefulness of measurement of soluble fibrin monomer-fibrinogen complex (SF)].
    Koga S
    Rinsho Byori; 2004 Apr; 52(4):355-61. PubMed ID: 15164605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.